Antifungal use in hospitalized adults in U.S. academic health centers

American Journal of Health-System Pharmacy

Volumn 68, Issue 5, 2011, Pages 415-418

  Pakyz, Amy L ^a   Gurgle, Holly E ^b   Oinonen, Michael J ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^c University HealthSystem Consortium ^*  (United States)

Author keywords

Antifungals; Drug use; Hospitals; Mycoses; Prescribing

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; BETA LACTAM; BETA LACTAMASE INHIBITOR; CARBAPENEM; CASPOFUNGIN; CEPHALOSPORIN; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VORICONAZOLE;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DRUG USE; HISTOPLASMOSIS; HOSPITAL PATIENT; HUMAN; INVASIVE CANDIDIASIS; MAJOR CLINICAL STUDY; ORGAN TRANSPLANTATION; PREDICTION; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT DURATION; UNITED STATES; UNIVERSITY HOSPITAL;

EID: 79956031869     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100423     Document Type: Article

References (10)

1. Pakyz AL, MacDougall C, Oinonen M et al. Trends in antibacterial use in US academic health centers. Arch Intern Med. 2008; 168:2254-60.
2. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32:470-85.
3. Horn DL, Neofytos D, Anaissie EJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009; 48:1695-703.
4. Prasad PA, Coffin SE, Leckerman KH et al. Pediatric antifungal utilization new drugs, new trends. Pediatr Infect Dis J. 2008; 27:1083-8.
5. Meyer E, Schwab F, Gastmeier P et al. Antifungal use in intensive care units. J Antimicrob Chemother. 2007; 60:619-24. (Pubitemid 47299878)
6. Boyd AE, Modi S, Howard SJ et al. Adverse reactions to voriconazole. Clin Infect Dis. 2004; 39:1241-4. (Pubitemid 40169325)
7. Eiden C, Peyrière H, Cociglio M et al; Network of the French Pharmacovigilance Centers. Adverse effects of voriconazole: analysis of the French pharmacovigilance database. Ann Pharmacother. 2007; 41:755-63. (Pubitemid 46752655)
8. Franci R. Breakthrough Candida dublinensis fungemia in an acute myeloid leukemia patient during voriconazole therapy successfully treated with caspofungin. J Chemother. 2009; 1:105-7.
9. Suzuki K, Sugawara Y, Sekine T et al. Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin. J Infect Chemother. 2009; 1:42-5.
10. Swoboda S, Lichtenstern C, Ober MC et al. Implementation of practice guidelines for antifungal therapy in a surgical intensive care unit and its impact on use and costs. Chemotherapy. 2009; 55:418-24.